BIRC5 and cancer: One possible approach to further improve selectivity for cancer versus benign cells could include using oncolytic viruses in combination with drugs that target cellular inhibitors of apoptosis (IAPs, e.g., Survivin, XIAP), as shown in our prior work with PIV5 infected respiratory cells [30].